Elekta demonstrate high definition dynamic radiosurgery with Versa HD and Monaco at ESTRO

Exhibit and events to highlight High definition Dynamic Radiosurgery with Versa HD and Monaco treatment planning software.

At the 36th ESTRO (European Society for Radiotherapy & Oncology) meeting, 5-9 May in Vienna, Elekta (EKTA-B.ST) will demonstrate the clinical flexibility of High definition Dynamic Radiosurgery (HDRS), a single oncology platform combining Versa HD™ linear accelerator and Monaco® treatment planning system.

HDRS supports clinicians to deliver high-volume advanced stereotactic therapies, such as stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) within standard treatment time slots.

Equipped with full-field, high definition beam-shaping technology and High Dose Rate modes, Versa HD offers end-to-end precision and accuracy to deliver a variety of stereotactic treatments throughout the body. Monaco enables efficient high definition planning and supports the Monte Carlo algorithm – the most accurate dose calculation available, ensuring lowest possible dose to critical structures while maintaining tight dose coverage to the target. The unique combination of Versa HD and Monaco allows the delivery of highly conformal and efficient stereotactic treatments in shorter or fewer arcs.

“With Elekta’s HDRS solutions, our team plans and delivers high doses and handles small, intricate fields without compromise. Many tumors located near critical organs or difficult-to-access areas require a level of precision not achievable with traditional linear accelerators, and this platform may be an important option for these individuals,” says Bora Tas, PhD, Chief Medical Physicist, Department of Radiation Oncology, Yeni Yuzyil University Medicine Faculty, Gaziosmanpasa Hospital, Istanbul, Turkey. “Versa HD also helps optimize clinical workflow, which should allow oncology departments to function efficiently and enable the treatment of more patients each day.”  

Stereotactic radiation therapies have become increasingly important cancer treatment modalities in recent years because they meet the demand for effective therapies that are low-cost, high value and address the needs of patients and clinicians. Elekta is committed to developing focused solutions that continue to enhance the precision and targeting of radiation therapy and allow our customers to provide their patients with optimal care and outcomes.”

Dr. Richard Hausmann, Elekta’s President and CEO.

Visitors to Elekta’s booth (#3000) will have the opportunity to participate in interactive demonstrations and learn more about recent Elekta innovations, including:

  • The role of magnetic resonance radiation therapy (MRT) and how research and development in this growing field is becoming a tangible reality. Join Elekta on Saturday 6 May at 10:10 when the future of MRT will become clear.
  • Venezia™, a new gynecological applicator now cleared for use in most markets, provides 3D image-guided adaptive brachytherapy for locally advanced cervical cancer. Venezia uniquely allows clinicians to treat IIIA and IIIB tumors in the cervix, parametrium and vaginal extensions through a combination of straight and oblique needles with consistent and reproducible placement.
  • Leksell Gamma Knife® Icon™, which offers clinicians unrivaled precision in frameless and frame-based treatment approaches for both single-session and fractionated SRS treatments. Learn how QA and planning are fast and intuitive for treating tumors adjacent to critical structures or multiple brain lesions.
  • MOSAIQ®, the leading comprehensive and open EMR, will be showcased through a virtual experience. Visitors will learn how they can unlock data into actionable analytics, make more informed decisions based on clinical and operational insights and manage cancer registries more efficiently with MOSAIQ Oncology Informatics.
Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors